Tag: Dicerna Pharmaceuticals

  • Worth Watching Stocks: Sony Corp (NYSE:SNE), Mylan Inc (NASDAQ:MYL), Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), La-Z-Boy Incorporated (NYSE:LZB)

    Sony Corp (NYSE:SNE) announced that the company sold a record seven million units of its PlayStation 4 console in the five months following the launch. Sony Corp (ADR) (NYSE:SNE) shares after opening at $18.75 moved to $18.81 on last trade day and at the end of the day closed at $18.78. Company price to sales ratio in past twelve months was calculated as 0.26 and price to cash ratio as 1.21. Sony Corp (ADR) (NYSE:SNE) showed a negative weekly performance of -0.21%.

    Mylan Inc (NASDAQ:MYL) has had its hand full having to deal with several litigations. The good news is that the company has successfully managed to get through most of them. These are outcomes of the efforts the company is undertaking to stake its claim in the worldwide drug empire. The company’s share has had its fair share of ups and downs and is recently on a downslide. Mylan Inc (NASDAQ:MYL) shares advanced 2.12% in last trading session and ended the day on $47.21. MYL return on equity ratio is recorded as 20.90% and its return on assets is 4.80%. Mylan Inc (NASDAQ:MYL) yearly performance is 68.49%.

    Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna’s first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares moved up 1.87% in last trading session and was closed at $16.30, while trading in range of $15.00-$16.75. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) year to date performance is -64.57%.

    La-Z-Boy Incorporated (NYSE:LZB) said Wednesday that it will restructure its casegoods business, which represents about 10% of revenue, by transitioning to an all-import model for its wood furniture.La-Z-Boy Incorporated (NYSE:LZB) weekly performance is -3.33%. On last trading day company shares ended up $24.98. La-Z-Boy Incorporated (NYSE:LZB) distance from 50-day simple moving average is -5.48%. Analysts mean target price for the company is $32.38.